Aimmune therapeutics, inc. (AIMT)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Dec'14
Assets
Current assets:
Cash and cash equivalents

298,418

79,880

76,844

72,564

81,058

107,511

78,420

142,157

209,324

73,487

73,821

84,451

78,714

124,010

76,911

74,430

65,045

76,677

112,661

58,502

2,269

Short-term investments

59,933

63,633

118,626

171,108

202,113

196,421

176,829

147,843

112,560

108,943

138,209

152,874

167,533

124,921

73,332

94,538

115,234

115,158

103,946

-

-

Trade receivables, net

772

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

4,076

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

4,621

5,564

6,766

6,859

8,220

8,687

6,543

6,826

8,413

6,681

6,063

5,287

2,625

2,749

2,338

3,782

4,952

5,622

-

-

106

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,180

2,105

-

Total current assets

367,820

149,077

202,236

250,531

291,391

312,619

261,792

296,826

330,297

189,111

218,093

242,612

248,872

251,680

152,581

172,750

185,231

197,457

217,787

60,607

2,375

Long-term investments

13,256

14,661

5,038

6,584

13,177

-

-

5,901

9,863

-

-

-

13,065

33,602

9,012

2,804

6,697

7,992

2,784

-

-

Property and equipment, net

27,506

28,604

28,713

29,414

26,824

26,328

25,045

23,265

21,021

17,205

14,940

13,142

11,147

10,391

9,034

7,032

3,699

2,702

1,829

1,253

87

Operating lease right-of-use assets

10,913

11,512

11,904

11,736

12,247

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

100

40

Prepaid expenses and other assets

557

515

507

511

514

608

626

664

664

618

637

600

3,205

3,116

3,100

3,110

4,302

4,210

-

-

29

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

314

114

-

Total assets

420,052

204,369

248,398

298,776

344,153

339,555

287,463

326,656

361,845

206,934

233,670

256,354

276,289

298,789

173,727

185,696

199,929

212,361

222,814

62,074

2,531

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

13,952

13,882

11,941

14,086

10,517

8,833

13,890

8,211

6,252

5,095

4,301

2,310

1,676

1,427

1,470

1,261

1,791

1,863

1,014

309

478

Accrued liabilities

29,128

31,286

29,480

27,083

25,588

29,144

23,545

27,844

24,127

21,478

16,848

15,622

8,440

9,921

10,249

4,433

3,395

3,118

1,848

2,796

1,259

Operating lease liabilities, current

2,315

2,257

2,163

2,022

1,967

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

24

23

21

20

19

35

16

39

33

26

38

108

107

102

128

150

133

117

238

222

67

Total current liabilities

45,419

47,448

43,605

43,211

38,091

38,012

37,451

36,094

30,412

26,599

21,187

18,040

10,223

11,450

11,847

5,844

5,319

5,098

3,100

3,327

1,804

Long term debt, net of discount

128,250

41,028

39,782

38,526

37,268

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

9,824

10,524

11,153

11,036

11,633

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

1,512

1,345

1,166

1,029

860

2,596

2,848

2,724

2,341

2,530

1,894

1,523

1,348

1,367

1,381

1,323

1,212

1,012

826

784

56

Total liabilities

185,005

100,345

95,706

93,802

87,852

40,608

40,299

38,818

32,753

29,129

23,081

19,563

11,571

12,817

13,228

7,167

6,531

6,110

3,926

4,111

1,860

Commitments and contingencies (Note 7)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

Stockholders’ equity:
Preferred stock, par value $0.0001 per share— 10,000 shares authorized at March 31, 2020 and December 31, 2019; 526 and 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

0

0

Common stock, par value $0.0001 per share—290,000 shares authorized as of March 31, 2020 and December 31, 2019; 65,223 and 63,779 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

7

6

6

6

6

6

6

6

6

5

5

5

5

5

4

4

4

4

4

-

-

Additional paid-in capital

1,045,989

828,618

810,328

798,058

786,681

775,283

666,532

655,490

644,193

443,390

434,974

429,445

424,862

420,151

269,562

265,489

262,244

259,668

256,211

2,464

1,260

Accumulated other comprehensive income

163

80

140

236

63

-108

-138

-123

-125

-108

-74

-135

-122

-27

14

31

6

-88

-2

-

-

Accumulated deficit

-811,100

-724,680

-657,800

-593,300

-530,400

-476,234

-419,236

-367,535

-314,982

-265,482

-224,316

-192,524

-160,027

-134,157

-109,081

-86,995

-68,856

-53,333

-37,325

-28,334

-17,517

Total stockholders’ equity

235,047

104,024

152,692

204,974

256,301

298,947

247,164

287,838

329,092

177,805

210,589

236,791

264,718

285,972

160,499

178,529

193,398

206,251

218,888

57,963

671

Total liabilities and stockholders’ equity

420,052

204,369

248,398

298,776

344,153

339,555

287,463

326,656

361,845

206,934

233,670

256,354

276,289

298,789

173,727

185,696

199,929

212,361

222,814

62,074

2,531